Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Patients with Alopecia Areata are willing to trade life duration for better quality of life.

Alopecia areata negatively affects family life, mental health, and quality of life in young people.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

Men with hair loss experience lower quality of life, worsened by factors like age, severity, and treatment history.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.

Serum calprotectin is not a reliable marker for alopecia areata activity.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

Patients were highly satisfied with shared medical appointments for hair loss treatment.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.

A Japanese patient with a rare genetic disorder had a less severe case than others, suggesting other factors may affect symptoms.

Different connective tissue disorders have unique symptoms and treatments, with varying outcomes and often require ongoing care from a specialist.

No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.

Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.

Tofacitinib is a safe and effective treatment for hair loss in children with Alopecia Areata.

Clinical signs don't match inflammation levels in lichen planopilaris and frontal fibrosing alopecia.

JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.

Secukinumab can cause hair loss, which may improve after stopping the medication.

Unique fat cells near fibrotic areas contribute to systemic sclerosis progression.

Narrowband Ultraviolet B treatment can significantly reduce anxiety in psoriasis patients, but it doesn't significantly affect depression.

Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.